company background image
600216 logo

Zhejiang Medicine SHSE:600216 Stock Report

Last Price

CN¥16.30

Market Cap

CN¥15.7b

7D

2.0%

1Y

55.1%

Updated

24 Dec, 2024

Data

Company Financials +

Zhejiang Medicine Co., Ltd.

SHSE:600216 Stock Report

Market Cap: CN¥15.7b

My Notes

Capture your thoughts, links and company narrative

Zhejiang Medicine Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zhejiang Medicine
Historical stock prices
Current Share PriceCN¥16.30
52 Week HighCN¥19.40
52 Week LowCN¥7.97
Beta0.085
1 Month Change2.13%
3 Month Change11.34%
1 Year Change55.09%
3 Year Change-1.87%
5 Year Change22.10%
Change since IPO486.69%

Recent News & Updates

Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch

Nov 22
Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch

We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings

Nov 01
We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings

Recent updates

Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch

Nov 22
Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch

We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings

Nov 01
We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings

Is Zhejiang Medicine (SHSE:600216) A Risky Investment?

Sep 14
Is Zhejiang Medicine (SHSE:600216) A Risky Investment?

What Zhejiang Medicine Co., Ltd.'s (SHSE:600216) 27% Share Price Gain Is Not Telling You

Aug 06
What Zhejiang Medicine Co., Ltd.'s (SHSE:600216) 27% Share Price Gain Is Not Telling You

Zhejiang Medicine (SHSE:600216) Is Reducing Its Dividend To CN¥0.15

Jul 05
Zhejiang Medicine (SHSE:600216) Is Reducing Its Dividend To CN¥0.15

The Market Doesn't Like What It Sees From Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Earnings Yet

Jun 21
The Market Doesn't Like What It Sees From Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Earnings Yet

Zhejiang Medicine's (SHSE:600216) Earnings Are Weaker Than They Seem

May 02
Zhejiang Medicine's (SHSE:600216) Earnings Are Weaker Than They Seem

Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet

Mar 29
Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet

Shareholder Returns

600216CN PharmaceuticalsCN Market
7D2.0%-3.1%-2.1%
1Y55.1%-4.4%9.8%

Return vs Industry: 600216 exceeded the CN Pharmaceuticals industry which returned -4.4% over the past year.

Return vs Market: 600216 exceeded the CN Market which returned 9.8% over the past year.

Price Volatility

Is 600216's price volatile compared to industry and market?
600216 volatility
600216 Average Weekly Movement6.7%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement8.8%
10% most volatile stocks in CN Market13.0%
10% least volatile stocks in CN Market5.8%

Stable Share Price: 600216 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 600216's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19976,227Chun Lei Luwww.zmc.top

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceutical products in China. The company products include synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also offers fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products.

Zhejiang Medicine Co., Ltd. Fundamentals Summary

How do Zhejiang Medicine's earnings and revenue compare to its market cap?
600216 fundamental statistics
Market capCN¥15.67b
Earnings (TTM)CN¥977.95m
Revenue (TTM)CN¥9.03b

16.0x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600216 income statement (TTM)
RevenueCN¥9.03b
Cost of RevenueCN¥5.75b
Gross ProfitCN¥3.28b
Other ExpensesCN¥2.30b
EarningsCN¥977.95m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.02
Gross Margin36.30%
Net Profit Margin10.83%
Debt/Equity Ratio7.1%

How did 600216 perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

15%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:19
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Medicine Co., Ltd. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiaofeng QiuChina International Capital Corporation Limited
Yilin HouChina International Capital Corporation Limited
Zheng ZhouChina Merchants Securities Co. Ltd.